The US Food and Drug Administration (FDA) has approved amantadine extended-release capsules (Gocovri, Adamas Pharmaceuticals Inc) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, the company announced on 8/25/17.
“Gocovri’s approval is an important advancement for […]
In a first, the US Food and Drug Administration (FDA) has approved a drug for use in patients who develop the life-threatening condition of chronic graft-vs-host disease (cGVHD) after having undergone a hematopoietic stem cell transplant (HSCT). The approval was received on August 2nd, 2017. […]
A new meta-analysis and systematic review finds mixed evidence to support use of artificial sweeteners for weight loss and suggests routine consumption may be associated with long-term weight gain and an increased risk of cardiometabolic disease. Nonnutritive sweeteners, such as aspartame, sucralose and
stevioside, are widely consumed, […]
On February 9th, 2017 the U.S. Food and Drug Administration (FDA) approved Emflaza® (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza® is a corticosteroid that works […]
The fight against the diversion of opioids and other controlled substances is heating up in the nation’s health systems, according to experts at a packed session at the 2016 annual meeting of the American Society of Consultant Pharmacists (ASCP). Two major factors are providing the wake-up call […]
Data from a new systematic review and meta-analysis provides evidence the pioglitazone can help prevent secondary stroke in people with abnormal glucose metabolism. Pioglitazone reduced major vascular events after ischemic stroke in a recent randomized controlled trial. The purpose of this study was to conduct a meta-analysis […]
On November 16th, 2016 the U.S. Food and Drug Administration (FDA) granted accelerated approval for Darzalex® (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex® is the first monoclonal antibody approved for treating multiple myeloma.
Multiple myeloma is a form of […]
Diabetes mellitus characterized by hyperglycemia is an increasing worldwide health problem. It is largely classified into insulin-dependent diabetes mellitus (type 1 diabetes) and noninsulin-dependent diabetes mellitus (type 2 diabetes). The type 2 diabetes (T2D) makes up more than 90% of all diabetes cases. Established risk factors for […]
On November 17th, 2016 the U.S. Food and Drug Administration (FDA) approved Intrarosa® (prasterone) manufactured by Quebec-based Endoceutics Inc.to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Intrarosa® is the first FDA […]
Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by persistent synovitis and systemic inflammation. Genetic predisposition as well as autoantibodies and environmental factors, such as smoking, are associated with an increased risk of RA. Traditionally RA has been treated with disease modifying anti-rheumatic drugs (DMARDs) […]